MedPath

Cohort Study for the Assessment of Long-term Impact of COVID-19 Among Mild COVID-19 Patients in Brazil

Active, not recruiting
Conditions
COVID-19
Quality of Life
Disability Physical
Disabilities Mental
Interventions
Other: Patients with symptomatic COVID-19 disease not requiring hospitalization.
Registration Number
NCT05197647
Lead Sponsor
Hospital Moinhos de Vento
Brief Summary

The present prospective cohort study aims to assess factors associated with of one-year health-related quality of life and physical, cognitive and mental health outcomes among adult patients with mild COVID-19. Adult patients with symptomatic COVID-19 not requiring hospitalization will be followed through structured and centralized telephone interviews performed at 1, 3, 6, 9 and 12 months after enrollment.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
1085
Inclusion Criteria
  • Age ≥18 years;
  • Positive polymerase chain reaction (PCR) test for SARS-CoV-2;
  • At least one of the following symptoms: fever, cough, sneezing, dyspnea, fatigue, smell alteration, rhinorrhea, sore throat, myalgia, arthralgia, diarrhea;
  • Outpatient COVID-19 care at the moment of enrollment (without indication for in-hospital care).
Read More
Exclusion Criteria
  • Severe comorbidity with life expectancy less than 3 months;
  • Absence of proxy for patients with communication difficulties;
  • Absence of telephone contact;
  • Refusal or withdrawal of agreement to participate;
  • Previous enrollment in the study.
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Patients with mild COVID-19Patients with symptomatic COVID-19 disease not requiring hospitalization.Patients with symptomatic COVID-19 disease not requiring hospitalization.
Primary Outcome Measures
NameTimeMethod
One-year utility score of health related quality of lifeThe outcome will be assessed 12 months after enrollment.

The outcome will be assessed using the Brazilian version of the Euroqol-5D-3L (EQ-5D3L) questionnaire. The utility score derived from the EQ5D-3L ranges from 0 (death) to 1 (perfect health).

Secondary Outcome Measures
NameTimeMethod
Utility score of health related quality of life at 3, 6, and 9 monthsThe outcome will be assessed at 3, 6, and 9 months after enrollment.

The outcome will be assessed using the Brazilian version of the Euroqol-5D-3L (EQ-5D3L) questionnaire. The utility score derived from the EQ5D-3L ranges from 0 (death) to 1 (perfect health).

Incidence of all-cause mortalityThe outcome will be assessed at 1, 3, 6, 9, and 12 months after enrollment.

Incidence of all-cause mortality

Prevalence of anxiety and depression symptomsThe outcome will be assessed at 3, 6, 9, and 12 months after enrollment.

Prevalence of anxiety and depression symptoms as assessed by the Hospital Anxiety and Depression Scale (anxiety and depression scores range from 0 to 21, with higher scores indicating worse symptoms).

Incidence of hospitalizationsThe outcome will be assessed at 1, 3, 6, 9, and 12 months after enrollment.

Incidence of all-cause hospitalizations

Prevalence of posttraumatic stress disorder symptomsThe outcome will be assessed at 3, 6, 9, and 12 months after enrollment.

Prevalence of posttraumatic stress disorder symptoms as assessed by the Impact Event Scale-6 (scores range from 0 to 24 with higher scores indicating worse symptoms).

Incidence of major cardiovascular eventsThe outcome will be assessed at 3, 6, 9, and 12 months after enrollment.

Incidence of major cardiovascular events (composite endpoint of non-fatal stroke, non-fatal acute myocardial infarction, or cardiovascular death)

Incidence of new symptomatic COVID-19 infectionThe outcome will be assessed at 3, 6, 9, and 12 months after enrollment.

Incidence of new symptomatic COVID-19 infection defined as recurrence of COVID-19-related symptoms with a positive PCR test for SARS-CoV-2 90 days after the index infection.

Incidence of return to work or studyThe outcome will be assessed at 3, 6, 9, and 12 months after enrollment.

Incidence of return to work or study among patients that were working or studying at the moment of COVID-19 diagnosis.

Prevalence of prolonged COVID-19 symptomsThe outcome will be assessed at 1, 3, 6, 9, and 12 months after enrollment.

Prevalence of prolonged COVID-19 symptoms defined as presence of dyspnea, cough, fatigue, muscular weakness, chest discomfort, joint pain, anosmia, hair loss, brain fog, insomnia, among others)

Prevalence of cognitive dysfunctionThe outcome will be assessed at 3, 6, 9, and 12 months after enrollment.

Prevalence of cognitive dysfunction as assessed by the Telephone Interview for Cognitive Status (TICS-m; scores ranging from 0 to 50 with lower scores indicating worse cognition).

Physical functional statusThe outcome will be assessed at 3, 6, 9, and 12 months after enrollment.

Physical functional status as assessed by the modified Barthel index (score ranges from 0 to 100; higher scores indicate less functional dependence).

Instrumental Activities of Daily LivingThe outcome will be assessed at 3, 6, 9, and 12 months after enrollment.

The outcome will be assessed using the Lawton \& Brody Instrumental Activities of Daily Living Scale (the score ranges from 0 to 8, with higher scores indicating less dependence).

Trial Locations

Locations (14)

Hospital Enseada Prime

🇧🇷

Vitória, ES, Brazil

Hospital Leo Orsi

🇧🇷

Itapetininga, SP, Brazil

Hospital Moinhos de Vento

🇧🇷

Porto Alegre, Rio Grande Do Sul, Brazil

Instituto Horizonti

🇧🇷

Belo Horizonte, MG, Brazil

Clinica Silvestre Santé

🇧🇷

Rio Branco, AC, Brazil

Hospital Metropolitano Célio de Castro

🇧🇷

Belo Horizonte, MG, Brazil

Hospital do Coração do Mato Grosso do Sul

🇧🇷

Campo Grande, MS, Brazil

Hospital Universitário de Ponta Grossa

🇧🇷

Ponta Grossa, PR, Brazil

Instituto Procardio

🇧🇷

Joinville, SC, Brazil

Hospital Vila Nova

🇧🇷

Porto Alegre, RS, Brazil

Hospital do Coração

🇧🇷

São Paulo, SP, Brazil

Hospital Santa Paula

🇧🇷

São Paulo, SP, Brazil

Hospital de Clínicas de Ribeirão Preto

🇧🇷

Ribeirão Preto, SP, Brazil

Hospital Alemão Oswaldo Cruz

🇧🇷

São Paulo, SP, Brazil

© Copyright 2025. All Rights Reserved by MedPath